Create a narrative

Cosmo Pharmaceuticals Community

SWX:COPN Community

2 Narratives written by author
0 Comments on narratives written by author
122 Fair Values set on narratives written by author

Create a narrative

Cosmo Pharmaceuticals

KA

Community Contributor

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Catalysts Preliminary Unaudited Revenue and Cash Revenue: €266.8 million, representing a year-on-year increase of 188% compared to €92.8 million in 2023. This includes significant project-based revenues from GI Genius™ and Winlevi® of €190.2 million.

CHF 87.47

FV

45.5% undervalued

11.00%

Revenue growth p.a.

8

0

81

about 2 months ago

Cosmo Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Clascoterone Trials Completion And AI Expansion Will Open Future Markets

Key Takeaways Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings. Focus on AI-driven applications and digital transformation bolsters market reach, revenue opportunities, and long-term efficiency.

CHF 103.37

FV

53.9% undervalued

6.91%

Revenue growth p.a.

1

0

24

22 days ago